Clinical Trial Update: Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update characterizing iodine-124 labeled Evuzumitide (AT-01) for systemic amyloidosis, including transthyretin amyloidosis. The study i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyloidosis
• Transthyretin Amyloidosis

Drugs mentioned

• Iodine-124 Evuzumitide (AT-01) (Evuzumitide)

Snippet

Sponsor: Oregon Health and Science University | Conditions: Amyloidosis, Transthyretin Amyloidosis | Phase 2 | Status: RECRUITING